Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Turn on, tune in: New York biotech scores $15M+ in chemogenetics bet

6 years ago

How to build CAR–M: Carl June protégé and his biotech publish first evidence in Nature Biotechnology

6 years ago

To arm the immune system for sustained attack against HIV, NIH scientists take to viral vectors

6 years ago

J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO

6 years ago

Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy

6 years ago

Hear hear! Ear gene therapy player Akouos draws $105M in fresh capital

6 years ago

Failure-prone Unum cuts jobs, loses scientific chief, and changes focus yet again

6 years ago

Woodford who? TCR-focused Immunocore soldiers on with $130M+ B round

6 years ago

Jim Wilson's gene therapy startup Passage Bio bucks market sentiments, raising upsized $216M IPO

6 years ago

Biogen makes another bold Alzheimer’s bet, dropping $350M upfront to partner with genome-editing focused Sangamo

6 years ago

Spark loses another top exec in the wake of $4.3B takeover by Roche — report

6 years ago

'The headlines are the headlines, but': BioMarin talks up potential savings as hemophilia gene therapy launch looms

6 years ago

Will a 'risk-off' mindset hasten cell therapy M&A? Iovance surges on buyout chatter

6 years ago

Biogen touts new evidence from the gene therapy company it wagered $800M on

6 years ago

Speedy review and no adcomm for BioMarin's pioneering hemophilia gene therapy

6 years ago

Gene therapy pioneer Kathy High has left Spark after completing $4.3B union with Roche

6 years ago

TCR-focused Immatics adds another marquee name to its list of partners: GSK

6 years ago

FDA slaps a hold on LogicBio and its gene editing plans — shares tumble

6 years ago

From mice to dogs, and someday man: George Church's gene therapy cocktail for aging-related diseases

6 years ago

Kymriah pioneer Carl June is back, with first US human evidence for CRISPR use in cancer

6 years ago

MD Anderson emerges with strong evidence for natural killer cell therapy, and Takeda looks like a winner

6 years ago

How much does it cost to bootstrap a gene therapy startup? Not too much if you're Jim Wilson, per Passage Bio's $125M IPO filing

6 years ago

Catalent chief John Chiminski triggers a $315M-plus wager on the booming cell therapy market now in the making

6 years ago

Resistant to CAR-T therapies? It's the cancer, not your immune system — study

6 years ago

First page Previous page 48 49 505152 53 54 Next page Last page